Matthew James Reilley MD
Gastrointestinal Cancer
Director, Phase 1 Clinical Trial Program Director, GI Medical Oncology Research Assistant Professor of Medicine, University of Virginia School of Medicine Department of Medicine, Division of Hematology/Oncology
Join to View Full Profile
1300 Jefferson Park AvenuePO Box 800716Charlottesville, VA 22908
Phone+1 434-297-5504
Dr. Reilley is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2016 - 2017- University of Texas M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2014 - 2017
University of Pennsylvania Health SystemResidency, Internal Medicine, 2012 - 2014- University of Pennsylvania Health SystemInternship, Internal Medicine, 2011 - 2012
The Warren Alpert Medical School of Brown UniversityClass of 2011, M.D.
Dartmouth Medical SchoolM.D, 2006 - 2008- Washington and Lee UniversityB.S., B.A., 2002 - 2006
Certifications & Licensure
VA State Medical License 2017 - 2026
TX State Medical License 2014 - 2017
PA State Medical License 2011 - 2014
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I Trial.Mirella Nardo, Mohamed A Gouda, Matthew J Reilley, Amadeo B Biter, Joann Lim
Journal of Immunotherapy and Precision Oncology. 2025-05-01 - Oesophageal adenocarcinoma presenting with synchronous brain metastases.Derek Petrosian, Camilo E Fadul, Matthew Reilley, Patrick Dillon
BMJ Case Reports. 2025-01-31 - 1 citationsA Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.Andrew L Coveler, Matthew J Reilley, Mark Zalupski, Teresa Macarulla, Christos Fountzilas
Clinical Cancer Research. 2024-10-15
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
